Keyphrases
Antidepressant Augmentation
46%
Aripiprazole
21%
Bupropion
46%
Catchphrases
15%
Clinical Deterioration
26%
Clinical Trials
52%
Cognitive Function
46%
Cognitive Performance
37%
Cost Differentials
46%
COVID-19
46%
COVID-2
46%
Episodic Memory
26%
Executive Function
33%
Final Ends
15%
Fluvoxamine
46%
Frequency Estimation
30%
Geriatric Depression
46%
Group-based
22%
High-frequency Data
15%
Hospice
23%
Hospice Enrollment
34%
Hospice Use
46%
Idiographic Assessment
15%
Incurable Illness
23%
Individualized Intervention
15%
Intervention Optimization
15%
IT Mindfulness
15%
Medicare
34%
Memory Function
19%
Mindfulness Training
92%
Mindfulness-based Stress Reduction
61%
Missouri
46%
Multiple Myeloma
46%
Myeloma
46%
Older Adults
100%
Older Patients
46%
Placebo
46%
Precision Medicine
46%
Psychedelic Therapy
46%
Quality of Life Improvement
23%
Randomized Clinical Trial
53%
Randomized Controlled Trial
61%
Remission
17%
Remote Trials
30%
Smartphone App
46%
Smartphone Technology
46%
Subjective Cognitive Concerns
19%
Treatment-resistant
46%
United States
43%
Well-being
17%
Medicine and Dentistry
Adverse Effect
5%
Antidepressant
46%
Antidepressant Medication
7%
Aripiprazole
21%
Behavioral Treatment
11%
Bupropion
46%
Clinical Trial
65%
Clinical Trial Design
11%
Cognition
11%
Comorbidity
11%
COVID-19
46%
Depressive Disorder
11%
Deterioration
26%
Diseases
23%
Dyspnea
6%
End of Life Care
11%
Fluvoxamine
46%
Health Care
5%
Health Care Cost
46%
Infection
6%
Intention-to-Treat Analysis
13%
Late Life Depression
46%
Medicare
34%
Mindfulness-Based Stress Reduction
11%
Mobile Health
11%
Multiple Myeloma
46%
Myeloma
46%
Nortriptyline
14%
Outpatient
46%
Overall Survival
11%
Oxygen Saturation
13%
Patient Preference
11%
Personalized Medicine
34%
Placebo
46%
Psychotomimetic
46%
Quality of Life
23%
Randomized Clinical Trial
6%
Randomized Controlled Trial
58%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Surveillance, Epidemiology, and End Results
11%
Treatment Resistant Depression
10%
Treatment Response
11%
